15 October 2015
Four Abstracts at ECCO from SCRI UK - UPDATED
SCRI UK is proud to announce four abstracts from Executive Medical Director Dr HT Arkenau at this weekend's 40th ESMO European Cancer Conference (ECC 2015) in Vienna.
The European Cancer Congress is a biennial congress which combines the efforts of the most important European oncology professionals with the aim of improving the prevention, diagnosis, treatment and care of cancer patients.
Key topics being discussed during the meeting focus on novel therapies designed to target genetic mutations that cause cancers to develop, and also immunotherapies, which are helping to arm the immune system to recognize and more effectively fight many types of cancer.
Click on the links below to view the abstracts:
- 27LBA - Oral Presentation
LATE-BREAKING ABSTRACT: Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination
Speaker: H.T. Arkenau
“We are encouraged to see the clinical momentum building in the ongoing study with TVB-2640. The progress we have seen in the clinical development of this FASN inhibitor has demonstrated an encouraging safety and efficacy profile, and I look forward to presenting our research updates for this first-in-class agent,” commented Dr. Arkenau.
Read the Press Release from 3V Biosciences >>>
And watch Dr Arkenau talk about this exciting new pathway with The European Medical Journal here:
- P160 / 817
PROACT: A new way of engaging and empowering patients that fundamentally changes our understanding of tolerability impacts in early clinical development. A. Hughes, D. Landers, T. Arkenau, B. O'Connor, J. Royle
And you can watch Dr Arkenau talk about it to The European Medical Journal below:
- P342 / 1571
Ideal Body Mass Index (BMI) is significantly different between curatively resected and metastatic colorectal cancer (CRC) patients on chemotherapy V. Formica, S. Pellicori, H.T. Arkenau, C. Morelli, J. Lucchetti, A. Nardecchia, S. Riondino, P. Ferroni, V. Cereda, M. Tesauro, F. Guadagni, M. Roselli
- P326 / 2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial. H.C. Chung, H.T. Arkenau, L. Wyrwicz, D.Y. Oh, K.W. Lee, J.R. Infante, K. Chin, A. von Heydebreck, Y.K. Kang, H. Safran
Dr Arkenau talks about these early promising results to The European Medical Journal below:
We are delighted that this abstract has also been accepted for Poster Discussion presentation during the ESMO Symposium on Immuno-Oncology - Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies, 20-21 November 2015, Lausanne, Switzerland.
It will also be published in the ESMO Symposium on Immuno-Oncology 2015 Abstract Book, a supplement to the official ESMO journal Annals of Oncology.
In addition, there were 10 other abstracts with authors from the global SCRI team.
<< Back to News